Heron Bay Capital Management Takes Position in Lantheus Holdings, Inc. $LNTH

Heron Bay Capital Management bought a new position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) in the 3rd quarter, HoldingsChannel reports. The fund bought 16,792 shares of the medical equipment provider’s stock, valued at approximately $861,000.

Several other large investors have also added to or reduced their stakes in LNTH. Stanley Laman Group Ltd. boosted its position in shares of Lantheus by 38.7% during the third quarter. Stanley Laman Group Ltd. now owns 79,686 shares of the medical equipment provider’s stock valued at $4,087,000 after buying an additional 22,229 shares during the last quarter. American Assets Inc. bought a new stake in shares of Lantheus in the 3rd quarter worth $872,000. Campbell & CO Investment Adviser LLC purchased a new stake in shares of Lantheus in the third quarter valued at about $2,184,000. Assetmark Inc. lifted its position in shares of Lantheus by 20.1% during the third quarter. Assetmark Inc. now owns 118,503 shares of the medical equipment provider’s stock valued at $6,078,000 after purchasing an additional 19,844 shares in the last quarter. Finally, Fox Run Management L.L.C. purchased a new position in Lantheus during the second quarter worth about $654,000. Institutional investors own 99.06% of the company’s stock.

Lantheus Stock Performance

NASDAQ:LNTH opened at $76.31 on Friday. The business’s fifty day moving average is $68.99 and its 200 day moving average is $60.79. Lantheus Holdings, Inc. has a 52-week low of $47.25 and a 52-week high of $111.29. The firm has a market cap of $4.93 billion, a price-to-earnings ratio of 22.64 and a beta of -0.11. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.51 and a current ratio of 2.70.

Lantheus (NASDAQ:LNTH) last posted its earnings results on Thursday, February 26th. The medical equipment provider reported $1.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.17 by $0.50. The business had revenue of $406.79 million for the quarter, compared to analysts’ expectations of $367.03 million. Lantheus had a net margin of 15.15% and a return on equity of 30.77%. The business’s revenue for the quarter was up 4.0% compared to the same quarter last year. During the same period in the prior year, the company posted $1.59 EPS. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Research analysts predict that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Analyst Ratings Changes

LNTH has been the subject of several analyst reports. William Blair upgraded shares of Lantheus from a “market perform” rating to an “outperform” rating in a research note on Thursday, February 26th. Mizuho increased their price target on Lantheus from $72.00 to $85.00 and gave the company an “outperform” rating in a research report on Friday, February 27th. Truist Financial upped their price objective on Lantheus from $82.00 to $89.00 and gave the company a “buy” rating in a research note on Friday, February 27th. Citizens Jmp lifted their target price on Lantheus from $73.00 to $78.00 and gave the stock a “market outperform” rating in a research note on Tuesday, February 24th. Finally, Citigroup restated an “outperform” rating on shares of Lantheus in a research report on Tuesday, February 24th. Seven investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $82.17.

Lantheus Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.